Enovis Corporation ENOV

SEC filings · Reporting currency USD · Quarterly reporting · Figures as of 2026-Q2 · updated 2026-09-06 · ISIN US1940145022

Guidance confirmed Revenue accelerating ◦

The new quarter, monitored by AI. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.

AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more

AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.

Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.

Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.

EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology

AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Business Model#

What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.

Enovis Corp is a global medical technology company specializing in orthopedic and musculoskeletal solutions, serving patients and healthcare providers across approximately 45 countries. The company operates through two principal segments: Reconstructive (Recon), which develops and commercializes joint replacement implants for hips, knees, and extremities, and Prevention & Recovery, which provides bracing, rehabilitation, and recovery products. Revenue is generated through direct sales forces and distribution channels, with procedure-volume growth in elective orthopedic surgeries serving as the primary demand driver. Enovos expanded its reconstructive footprint through the acquisition of Lima Orthopaedics, a European implant manufacturer, meaningfully increasing its international exposure. The company pursues organic growth through product innovation and commercial execution, supplemented by targeted bolt-on acquisitions of distributors, businesses, and intellectual property. Capital allocation is balanced between investment in organic growth, debt reduction following recent large acquisitions, and selective inorganic transactions.

Current Status#

Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.

Enovis Corp reported second-quarter 2026 net sales of $582.8 million, a 3.2% increase on a reported basis and approximately 5% on an organic basis versus the prior year, driven by existing business growth and favorable foreign currency translation ³⁰ ³¹. The Reconstructive segment led performance with 8% reported and 6% organic net sales growth in the quarter ³¹. Adjusted EBITDA reached $104 million, or 17.9% of net sales, and adjusted earnings per diluted share rose to $0.90 from $0.72 in the second quarter of 2025 ³¹. Full-year 2026 guidance was reaffirmed across all key financial metrics ³¹.

Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-08-06):

„Our second-quarter results reflect a more focused organization and a portfolio that has been meaningfully reshaped over the past several years. Commercial execution is improving, our innovation pipeline continues to strengthen our competitive positioning, and our teams are demonstrating agility in navigating increasingly dynamic end markets. We are encouraged by this progress but acknowledge there is more work ahead to deliver consistent durable growth, particularly as we anticipate a more dynamic macroeconomic environment in the second half. We remain focused on winning each day through continuous improvement, and disciplined execution.“ – Damien McDonald, Chief Executive Officer ³¹

Revenue · 2026-Q2583$m+3.2 % vs. 2025-Q2

Net profit · 2026-Q2-1$m+97.3 % vs. 2025-Q2

EPS · 2026-Q2-0.02$+96.9 % vs. 2025-Q2

Revenue trend

Guidance

For FY2026, the company guides Organic revenue growth to 4-6% (confirmed); Free cash flow conversion to 25% or higher (confirmed); Revenue to $2.31-2.37 billion (confirmed). ³¹.

Profitability

Operating income for the quarter was $17.4 million on net sales of $582.8 million, with a GAAP net loss of $1.0 million, or -$0.02 per diluted share ¹³¹. Adjusted EBITDA of $104 million (17.9% of net sales) reflects the differential between reported and adjusted results attributable to non-cash and other charges ³¹. Free cash flow was $31.1 million, generated from operating cash flow of $75.0 million net of capital expenditures of $43.9 million ¹³¹.

Leverage

Net debt at quarter end was $1,309.3 million, with a cash position of $12.6 million ¹³¹. Full-year 2026 adjusted EBITDA guidance of $425–$435 million provides a reference point for the leverage trajectory over the remainder of the year ³¹. Debt agreements include covenants that restrict the company's operating and acquisition flexibility ³⁰.

Management view

Full-year 2026 revenue guidance of $2.31–$2.37 billion was reaffirmed, incorporating 4–6% organic growth, alongside adjusted EBITDA guidance of $425–$435 million and adjusted EPS of $3.52–$3.73 ³¹. Free cash flow conversion guidance of 25% or higher was also maintained for the full year ³¹. Management identified strengthening of the innovation pipeline as a planned strategic priority for upcoming periods ³¹.

Change

The Dr. Comfort Footcare Solutions U.S. operations were divested to Promus Equity Partners in October 2025 for up to $60 million, reducing the company's non-orthopedic product portfolio, and the transaction was referenced in the Q2 2026 filing as a portfolio-shaping action ³⁰. The GAAP net loss of $1.0 million for the quarter contrasts with adjusted EBITDA of $104 million, indicating material non-cash and integration-related charges below the operating line ¹³¹ ³¹. Seven bolt-on transactions completed during 2025 for total purchase consideration of $36.9 million–including distributor, business, and IP acquisitions–introduced ongoing integration activity into the current operating environment ³⁰.

Risks (current)

Enovis derives 44–45% of sales from non-U.S. operations and is exposed to foreign exchange movements that can impact reported results; management additionally cited expectations of a more dynamic macroeconomic environment in the second half of 2026 ³⁰ ³¹. The company faces product liability claims and legal proceedings inherent to medical device operations, and must maintain and defend its intellectual property rights in orthopedic solutions ³⁰ ²⁸. Debt covenants limit operational and acquisition flexibility, and the integration of the Lima Acquisition carries execution risk that could adversely affect financial results ³⁰ ²⁸ ²⁶.

Price & Chart#

Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Share-Price Drivers#

Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.

Reconstructive segment growth led by the Lima integration
Reconstructive revenue rose 5.5% to $317.1m in the latest quarterly cut with U.S. Reconstructive up 8.2%, outpacing the slower-growing Prevention & Recovery segment and anchored by ongoing integration of the LimaCorporate acquisition (²⁹, ³⁰)

Reconstructive segment (hip/knee/shoulder, extremities) traction
Reconstructive revenue +5.5% to $317.1m and U.S. Reconstructive +8.2% to $149.2m in the latest quarter, the fastest-growing part of the portfolio (²⁹)

Lima acquisition integration and revenue synergies
Lima integration cited as ongoing into 2026-Q2 following the 2023 acquisition, supporting Reconstructive scale (³⁰, ²⁶)

Prevention & Recovery segment demand
P&R revenue roughly flat at $272.0m (+1.0%), with U.S. Bracing & Support down 0.2% and U.S. Other P&R up 2.9% (²⁹)

Product/innovation cadence (Arvis 2.0, Altivate Reverse Glenoid, ROAM OA, pipeline)
Multi-year cadence of launches across Recon and P&R plus stated strengthening of the innovation pipeline in 2026-Q2 (¹¹, ¹⁵, ³¹)

Portfolio reshaping via bolt-on M&A and divestitures
Seven acquisitions in 2025 (distributors, businesses, IP) alongside divestiture of Dr. Comfort footcare and the hosiery line, concentrating on core Recon and P&R (²⁶, ²⁸, ³⁰)

Balance-sheet leverage and impairment overhang
Net debt near $1.31bn and large operating losses in 2025-Q3/Q4 (operating income -$558.5m and -$502.2m) from impairment charges, partly addressed by Credit Facility Amendment No. 3 (¹³¹, ¹²⁷, ¹²⁵, ²⁶)

Cash generation and adjusted profitability
Latest quarter adjusted EPS $0.90, operating cash flow $75.0m and free cash flow $31.1m, with change flags noting accelerating growth, improving profitability and confirmed guidance (¹³¹)

Sector trend: Orthopedic device demand is expanding, with Reconstructive procedure volumes growing faster than bracing/recovery products and reported segment gross margins high (Recon ~65.8%, P&R ~54.0% in FY2025) (²⁹, ²⁶). Headline profitability remains pressured by non-cash impairment charges and elevated leverage even as adjusted earnings and cash flow improve (¹³¹, ¹²⁷).

Event Timeline#

This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.

Overview: one dot per event · click jumps to the period

2026 · 7 events

2026-Q2 · Apr – Jun 2026

earnings 2026-08-06
Adjusted EPS $0.90 vs. $0.72 in Q2 2025; adjusted EBITDA $104M at 17.9% margin ³¹

Revenue accelerating ◦ 2026-08-06
Net sales +3.2% reported (+5% organic) to $582.8M; Reconstructive segment +7.5% with 6.3% existing business growth; six-month net sales +4.3% ³⁰ ³¹

Guidance confirmed 2026-08-06
Full-year 2026 guidance reaffirmed: revenue $2.31-2.37B (4-6% organic growth), adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73, free cash flow conversion >=25% ³¹

2026-Q1 · Jan – Mar 2026

„Our first-quarter results reflect solid execution and continued progress advancing our innovation-led strategy. Growth in the quarter was supported by contributions from recent product launches which enhance our competitive positioning and expand our addressable market. At the same time, we are operating in a dynamic macroeconomic and geopolitical environment, and we remain focused on disciplined execution. Our priorities - commercial execution and innovation, operational excellence, and financial discipline - position us well to navigate near-term uncertainty while continuing to invest in long-term growth. We remain confident in our strategy and our ability to deliver sustainable performance and value for patients and shareholders over time.“ – Damien McDonald, Chief Executive Officer ²⁹

Revenue accelerating ◦ 2026-05-07
Net sales +5.4% to $589.2M (organic +3.3%, FX +4.2%); Reconstructive segment +10.8% to $317.1M on existing business growth of 5.5%; Prevention & Recovery segment flat at $272.0M, impacted by Dr. Comfort divestiture headwind ²⁸

Margin expanding 2026-05-07
Gross margin +260bps to 62.0%; adjusted EBITDA +19.0% to $103.6M with margin +210bps to 17.6%, driven by higher volumes, improved product mix, and lower inventory step-up charges ²⁸

Guidance confirmed 2026-05-07
Full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion guidance reiterated ²⁹

Operating income turned positive 2026-05-07
Operating income turned positive for the first time after 14 negative periods (-502.2 to +6.5 USDm). ¹²⁹

2025 · 16 events

2025-Q4 · Oct – Dec 2025

„As we enter 2026, our focus remains consistent and disciplined – driving commercial execution, advancing our rich innovation pipeline, improving operational efficiency, and maintaining financial discipline – as we position the Company for durable, capital-efficient growth while remaining attentive to the evolving macro environment.“ – Damien McDonald, Chief Executive Officer ²⁷ (translation – original on hover)

earnings 2026-02-26
Q4 net loss from continuing operations of $519M included a $501M non-cash goodwill impairment charge; full-year net loss of $1,182M included $1,050M total goodwill impairment, both triggered by sustained decline in share price and market capitalization (²⁷)

EBITDA turned positive 2026-02-26
Full-year 2025 adjusted EBITDA reached $403M, up from $376.5M in 2024, driven by increased gross profit and improved operating cost leverage (²⁶, ²⁷)

Guidance initiated 2026-02-26
2026 guidance initiated with 4-6% organic revenue growth and full-year revenue expected at $2.31-2.37B (²⁷)

2025-Q3 · Jul – Sep 2025

„We delivered solid results in the third quarter, reflecting continued progress by our teams around the world. Execution was driven by double-digit growth in extremities and consistent performance across Prevention & Recovery. As we position Enovis for its next phase of profitable, capital-efficient growth, we are focusing on the near-term strategic priorities of commercial execution and innovation, operational excellence, and financial discipline.“ – Damien McDonald, Chief Executive Officer ²⁵

earnings 2025-11-06
Non-cash goodwill impairment charge of $548.4M recognized in Q3, driven by sustained decline in the company's publicly quoted share price and market capitalization, resulting in Q3 net loss of $571M (²⁴, ²⁵)

Revenue accelerating ◦ 2025-11-06
Net sales grew 8.7% reported and 7% organic to $548.9M, with Reconstructive segment at 9% organic and Prevention & Recovery at 4% organic, both above Q2 organic growth rates (²⁴, ²⁵)

Divestiture 2025-11-06
Divestiture of Dr. Comfort Footcare Solutions U.S. operations to Promus Equity Partners completed for up to $60M ($45M upfront, up to $15M contingent on milestones), removing the unit from the Prevention & Recovery segment (²⁴, ²⁵)

2025-Q2 · Apr – Jun 2025

„My first 90 days have strengthened my belief that Enovis has the foundation, portfolio, and momentum to drive durable, profitable growth. Realizing this potential will require continued operational discipline and a sharp focus on scalable, capital efficient execution. We are in the early stages of unlocking the full value of our orthopedic platform, and I'm excited to lead the Company with a commitment to continue helping millions of people lead full, active lives with a focus on creating shareholder value. Our second-quarter performance reflects the strength of our diversified global portfolio and the opportunity ahead. I'm grateful to the Board and the entire Enovis team for their support and alignment on our strategy.“ – Damien McDonald, Chief Executive Officer ²³

Revenue decelerating ◦ 2025-08-07
Net sales grew 7.5% reported and 5% organic to $564.5M; Reconstructive segment at 8% organic and Prevention & Recovery at 3% organic, each below Q1 comparable growth rates (²², ²³)

Margin expanding 2025-08-07
Q2 gross profit margin improved 430 basis points, driven by reduced inventory fair value step-up amortization from the Lima acquisition and supply chain productivity gains (²²)

Guidance raised 2025-08-07
Full-year 2025 revenue guidance raised to $2.245-2.275B from prior $2.220-2.250B; adjusted EBITDA guidance raised to $392-402M from $385-395M; adjusted EPS guidance raised to $3.05-3.20 from $2.95-3.10 (²³)

Cash flow inflection 2025-08-07
Operating cash flow reached 47.8 USDm vs 7.8 USDm in 2024-Q2 (×6.1). ¹²³

2025-Q1 · Jan – Mar 2025

„We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations. This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment. As we move forward, we remain focused on driving above-market growth through disciplined execution, strategic investment, and a multi-year cadence of high-impact product launches across our portfolio.“ – Matt Trerotola, Chief Executive Officer ²¹

revenue 2025-05-08
Net sales grew 8.2% to $558.8M, led by Reconstructive segment (+11.3%) and Prevention & Recovery segment (+5.2%) (²⁰)

Revenue decelerating 2025-05-08
Revenue growth decelerated to +8.2% YoY (prior period +23.3%). ¹²⁹

Strategic pivot 2025-05-08
Damien McDonald appointed CEO effective May 12, 2025 (²¹)

Guidance initiated 2025-05-08
Full-year 2025 revenue guidance set at $2.22-2.25B and adjusted EBITDA at $385-395M, incorporating approximately $20M in tariff-related headwinds (²¹)

earnings 2025-02-26
Full-year adjusted EBITDA increased to $376.5M (17.9% margin) from $269.2M (15.8%) in 2023, driven by Lima integration contributions ¹⁸

Margin compressing 2025-02-26
Full-year gross profit margin decreased 200 bps to 56.0%, primarily due to $51.6M cumulative inventory fair value step-up amortization charges from Lima Acquisition ¹⁸

2024 · 14 events

FY2024 · Jan – Dec 2024

Segment divergence 2026-02-26
Reconstructive (Recon) revenue grew +60.2% to 1,009.7 USDm in FY2024 (48% of group revenue) while group revenue changed -38.3%. ²⁶

2024-Q4 · Oct – Dec 2024

„Our performance in 2024 marks a transformational year for the company as we executed our integration plans and solidified our ability to deliver sustainable high-single-digit organic growth and year-over-year margin expansion. Our strong finish in 2024 has set a solid foundation for 2025 with key new product launches positioned to drive above market growth rates.“ – Matt Trerotola, Chief Executive Officer ¹⁹

earnings 2025-02-26
Non-cash goodwill impairment charge of $645M ($330M Reconstructive, $315M Prevention & Recovery) recorded due to sustained decline in publicly quoted share price and market capitalization, driving Q4 net loss of $703.9M and full-year net loss of $825.5M ¹⁸ ¹⁹

Revenue accelerating 2025-02-26
Q4 net sales +23% on reported basis to $561M with strong growth in Global Reconstructive including Lima acquisition benefits ¹⁹

Guidance initiated 2025-02-26
2025 guidance initiated: revenue $2.19-$2.22B (6-6.5% organic growth), adjusted EBITDA $405-$415M, adjusted EPS $3.10-$3.25 ¹⁹

Operating cash flow turned positive 2025-02-26
Operating cash flow turned positive on a half-year basis (2024-H1: -28.4 to 2024-H2: +141.9 USDm, aggregated from reported quarters where needed). ¹²⁷

2024-Q3 · Jul – Sep 2024

„Our performance this quarter reflects the significant progress of our integration efforts and represents a return to above market growth rates in Recon. We are closing in on a strong finish for 2024 that will propel us into 2025 as we shift our focus from integration to growth, fueled by a robust lineup of important new product introductions across all areas of our business.“ – Matt Trerotola, Chief Executive Officer ¹⁷

revenue 2024-11-06
Net sales +21.0% to $505.2M on reported basis; Reconstructive segment grew 56.9% with $68.4M attributable to Lima; comparable growth 6% ¹⁶ ¹⁷

Margin expanding 2024-11-06
Adjusted EBITDA margin expanded 220 bps to 17.9% of sales, driven by Lima contributions ¹⁷

Guidance raised 2024-11-06
Full-year adjusted EPS guidance raised from $2.62-$2.77 to $2.75-$2.80; full-year revenue guidance narrowed to $2.10B ¹⁷

2024-Q2 · Apr – Jun 2024

„We continue to execute against our plan for the year and are off to a great start integrating our transformational Lima acquisition. The progress we have made year-to-date, as well as our robust lineup of important new product introductions, sets us up well for accelerating growth and profitability into 2025 and beyond.“ – Matt Trerotola, Chief Executive Officer ¹⁵

revenue 2024-08-07
Net sales +22.6% to $525.2M on reported basis; Recon segment grew 59.6% led by Lima and Novastep contributions of $90.1M; comparable growth 5% ¹⁴ ¹⁵

Margin compressing 2024-08-07
Gross profit margin decreased 3.0% in Q2 due to $23.9M inventory fair value step-up amortization charges from Lima Acquisition ¹⁴

Guidance raised 2024-08-07
Full-year adjusted EPS guidance raised from $2.52-$2.67 to $2.62-$2.77 ¹⁵

2024-Q1 · Jan – Mar 2024

„We had a great start to 2024, with both revenues and operating margins exceeding expectations. Our acquisition of Lima is a transformative milestone and reinforces our ability to innovate and take incremental market share in the global orthopedic market. The integration is progressing according to plan and we remain in the early stages of a multi-year cadence of new product introductions across Recon and P&R.“ – Matt Trerotola, Chief Executive Officer ¹³

Revenue accelerating ◦ 2024-05-02
Net sales +27.1% to $516.3M, primarily from Lima Acquisition and organic growth in existing businesses; proforma growth 5% ¹² ¹³

Margin expanding 2024-05-02
Adjusted EBITDA margin improved 220 bps year-over-year to 16.1% of sales ¹³

Acquisition 2024-05-02
LimaCorporate S.p.A. acquisition closed for $865.6M net of acquired cash, expanding Recon segment internationally with digital innovation and customized hardware solutions ¹² ¹⁸

2023 · 14 events

2023-Q4 · Oct – Dec 2023

„We are very pleased with our results in 2023 with both revenues and operating margins exceeding expectations while continuing to make investments in key growth initiatives and M&A. We look forward to carrying this momentum into 2024, which is setting up to be a transformative year as we integrate Lima and kick off a multi-year cadence of new product introductions across Recon and P&R.“ – Matt Trerotola, Chief Executive Officer ¹¹

Revenue accelerating ◦ 2024-02-22
Q4 net sales grew 11% to $455M with 8% organic growth; full-year net sales reached $1.7B, up 9% with 8% organic growth; Reconstructive segment delivered 18% full-year growth with 14% organic growth ¹¹

Margin expanding 2024-02-22
Full-year adjusted EBITDA margin improved 70 basis points year-over-year to 16% of sales, driven by product and geographic mix and new product introductions ¹¹

Guidance initiated 2024-02-22
2024 guidance initiated: revenue $2.05-$2.15B (including Lima contribution of $290-$300M), adjusted EBITDA $365-$380M, adjusted EPS $2.50-$2.65 ¹¹

Net income turned positive 2024-02-22
Net income turned positive for the first time after 5 negative periods (-2.8 to +3.1 USDm). ¹¹⁹

2023-Q3 · Jul – Sep 2023

„We are well positioned to achieve our 2023 goals of high-single digit growth and strong margin expansion. We made a significant move to accelerate our growth and margin profile with the pending acquisition of LimaCorporate and are excited by our operational momentum and the strength of our R&D pipeline.“ – Matt Trerotola, Chief Executive Officer ⁹

Net cash to net debt 2023-11-07
Issued $460M aggregate principal of senior unsecured convertible notes (3.875%, maturing 2028) in October 2023, materially increasing net debt in connection with Lima acquisition financing ⁸

Guidance raised 2023-11-07
Full-year organic revenue growth guidance raised to 7.4-7.6%; adjusted EBITDA raised to $264-$270M; adjusted EPS raised to $2.30-$2.40 ⁹

Acquisition 2023-11-07
Definitive agreement entered to acquire LimaCorporate S.p.A. for approximately €800M enterprise value, intended to strengthen and further globalize the Reconstructive segment ⁹

2023-Q2 · Apr – Jun 2023

„We are very pleased with our first half 2023 results of high-single digit growth and strong margin expansion. We continue to make progress on our strategic goals and have robust operating momentum in both of our business segments. As we look to the balance of the year, we will maintain our focus on innovation-driven share gain, operational improvement with EGX, and compounding impact from M&A.“ – Matt Trerotola, Chief Executive Officer ⁶

Margin expanding 2023-08-03
Gross profit margin improved to 58.0% from 54.6% year-over-year; fourth consecutive quarter of year-over-year gross margin improvement ⁵ ⁶

Guidance raised 2023-08-03
Full-year organic revenue growth guidance raised to 7-7.5% from prior 6-7%; adjusted EBITDA guidance raised to $262-$270M; adjusted EPS guidance raised to $2.22-$2.36 ⁶

Acquisition 2023-08-03
Novastep acquired on June 28, 2023 for $97.9M, a minimally invasive surgery foot and ankle solutions provider, expanding the Reconstructive segment ⁵

Operating cash flow turned positive 2023-08-03
Operating cash flow turned positive on a half-year basis (2022-H2: -16.6 to 2023-H1: +35.6 USDm, aggregated from reported quarters where needed). ¹¹⁵

2023-Q1 · Jan – Mar 2023

„We had a great start to the 2023 fiscal year, exceeding our expectations with strong organic growth and expanding margins while supporting key investments in innovation and acquisitions. We outperformed our markets with double-digit organic growth in Recon and mid-single-digit organic growth in P&R. We look forward to continuing our operating momentum while deploying our strong balance sheet against a robust M&A pipeline.“ – Matt Trerotola, Chief Executive Officer ⁴

Revenue accelerating ◦ 2023-05-04
Q1 net sales grew 8% to $406.2M with 9% organic growth; Reconstructive segment grew 19% organically and Prevention and Recovery grew 4% organically ³

Margin expanding 2023-05-04
Gross profit margin expanded to 57.9% from 54.8% year-over-year, benefiting from volume growth, pricing increases, and improved operating leverage ³

Guidance raised 2023-05-04
Full-year organic revenue growth guidance raised to 6-7% from prior 5-6%; adjusted EBITDA raised to $259-$267M; adjusted EPS raised to $2.18-$2.32 ⁴

Key Figures ($m)#

The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Basis Metric

Revenue ($m) · annual basis, as reported

Net income ($m) · annual basis, as reported

EPS ($) · annual basis, as reported

Operating cash flow ($m) · annual basis, as reported

Revenue ($m) · quarterly basis, as reported

Net income ($m) · quarterly basis, as reported

EPS ($) · quarterly basis, as reported

Operating cash flow ($m) · quarterly basis, as reported

Cash ($m) · annual basis, as reported

Debt ($m) · annual basis, as reported

Net Debt ($m) · annual basis, as reported

Capex ($m) · annual basis, as reported

FCF ($m) · annual basis, as reported

D&A ($m) · annual basis, as reported

Cash ($m) · quarterly basis, as reported

Debt ($m) · quarterly basis, as reported

Net Debt ($m) · quarterly basis, as reported

Capex ($m) · quarterly basis, as reported

FCF ($m) · quarterly basis, as reported

D&A ($m) · quarterly basis, as reported

Shown: the most recent fiscal years. Full history since FY2016 is on record.

Fiscal years

Amounts in $m · EPS in $ per share · as reported

Period	Revenue	Op. income	Net income	EPS ($)	EPS adj. ($)	EBITDA (adj.)	OCF	Source
FY2025	2,248	-1,124.2	-1,184.4	-20.75	3.30	403	217.3	¹²⁷
FY2024	2,107.6	-775.7	-825.5	-14.93	2.84	216.9	113.5	¹¹⁹
FY2023	1,707.2	-65.7	-33.3	-0.61	2.40	269.2	135	¹¹⁹

Quarters

Amounts in $m · EPS in $ per share · Net Debt/EBITDA as a multiple · as reported

Period	Published	Revenue	Op. income	Net income	EPS ($)	EPS adj. ($)	EBITDA (adj.)	FCF	Cash	Net Debt	Net Debt/EBITDA (x)	Source
2026-Q2*	2026-08-06	582.8	17.4	-1	-0.02	0.90	104.3	31.1	12.6	1,309.3	–	¹³¹
2026-Q1*	2026-05-07	589.2	6.5	-8.4	-0.15	0.89	103.6	-28.9	33.1	1,327.8	–	¹²⁹
2025-Q4*	2026-02-26	575.8	-502.2	-521.3	-9.13*	0.95	111.9	32.3	36.4	1,295.4	–	¹²⁷
2025-Q3*	2025-11-06	548.9	-558.5	-571.1	-9.99	0.75	94.8	29.1	33.6	1,345.9	–	¹²⁵
2025-Q2*	2025-08-07	564.5	-16.8	-36.5	-0.64	0.72	46.7	3.4	44.1	1,369.5	–	¹²³
2025-Q1*	2025-05-08	558.8	-46.8	-55.7	-0.98	0.65	30.9	-44.9	38.5	1,369.1	–	²⁰
2024-Q4*	2025-02-26	561	-664.7	-703.9	-12.73*	0.98	112.9	35.1	48.2	1,301.4	–	¹⁸
2024-Q3*	2024-11-06	505.2	-31.7	-31.3	-0.58	0.73	90.2	2.4	35.4	1,330.1	–	¹⁶
2024-Q2*	2024-08-07	525.2	-44.2	-18.5	-0.34	0.62	90.2	-31.6	35	1,324.5	–	¹¹⁵
2024-Q1*	2024-05-02	516.3	-35	-71.8	-1.32	0.50	83.2	-73.1	66.3	1,292.4	–	¹²
2023-Q4*	2024-02-22	455	-5.8	3.1	0.06*	0.79	81.7	40.5	36.2	430	2.8x (LTM)	¹⁰
2023-Q3*	2023-11-07	417.5	-20.5	-2.8	-0.05	0.56	65.4	4	32.1	362.9	3.4x (LTM)	⁸
2023-Q2*	2023-08-03	428.5	-14.5	-9.8	-0.18	0.61	65.7	-8.7	32.5	367.5	–	⁵
2023-Q1*	2023-05-04	406.2	-25	-23.2	-0.43	0.44	56.4	-23	21.9	263.1	–	³

* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.

Columns not reported in this reporting cadence are hidden: Op. income (adj.) (not reported in any source for these periods).

Balance Sheet & Cash Flow ($m)#

Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

Fiscal years

Amounts in $m · as reported

Period	Published	Cash	Debt	Net Debt	D&A	OCF	Capex	FCF	Source
FY2025	2026-02-26	36.4	1,331.8	1,295.4	1,344.1	217.3	197.4	19.9	¹²⁷
FY2024	2025-02-26	48.2	1,349.5	1,301.4	927.8	113.5	180.7	-67.2	¹¹⁹
FY2023	2024-02-22	36.2	466.2	430	217.1	135	122.2	12.8	¹⁰

Quarters

Amounts in $m · as reported

Period	Published	Cash	Debt	Net Debt	D&A	OCF	Capex	FCF	Source
2026-Q2	2026-08-06	12.6	1,321.9	1,309.3	71	75	43.9	31.1	¹³¹
2026-Q1	2026-05-07	33.1	1,361	1,327.8	73.4	24	52.8	-28.9	¹²⁹
2025-Q4	2026-02-26	36.4	1,331.8	1,295.4	1,126.8	88.5	56.3	32.3	¹²⁷
2025-Q3	2025-11-06	33.6	1,379.5	1,345.9	74.4	82.6	53.5	29.1	¹²⁵
2025-Q2	2025-08-07	44.1	1,413.6	1,369.5	71.6	47.8	44.4	3.4	¹²³
2025-Q1	2025-05-08	38.5	1,407.6	1,369.1	71.4	-1.6	43.3	-44.9	²⁰
2024-Q4	2025-02-26	48.2	1,349.5	1,301.4	717.4	88.3	53.2	35.1	¹⁸
2024-Q3	2024-11-06	35.4	1,365.5	1,330.1	71.2	53.6	51.2	2.4	¹⁶
2024-Q2	2024-08-07	35	1,359.5	1,324.5	65.8	7.8	39.4	-31.6	¹¹⁵
2024-Q1	2024-05-02	66.3	1,358.7	1,292.4	73.4	-36.2	36.9	-73.1	¹²
2023-Q4	2024-02-22	36.2	466.2	430	56.6	68.4	27.9	40.5	¹⁰
2023-Q3	2023-11-07	32.1	395	362.9	55.5	31	27	4	⁸
2023-Q2	2023-08-03	32.5	400	367.5	97.4	28.1	36.8	-8.7	⁵
2023-Q1	2023-05-04	21.9	285	263.1	7.6	7.5	30.4	-23	³

Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Revenue by Type (as of 2026-Q2 · USDm · 10/12)#

Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.

Segment	Since	Period	Basis	Revenue	Growth	Margin	Source
Reconstructive	2022-Q1	2026-Q1	3M	317.1	5.5%	–	²⁹
Prevention & Recovery	2022-Q1	2026-Q1	3M	272	1%	–	²⁹
International Reconstructive	2026-Q1	2026-Q1	3M	167.9	3%	–	²⁹
U.S. Reconstructive	2026-Q1	2026-Q1	3M	149.2	8.2%	–	²⁹
U.S. Bracing & Support	2026-Q1	2026-Q1	3M	114.9	-0.2%	–	²⁹
International P&R	2026-Q1	2026-Q1	3M	101.3	0.9%	–	²⁹
U.S. Other P&R	2026-Q1	2026-Q1	3M	55.9	2.9%	–	²⁹
Prevention and Recovery	2023-Q1	2025-Q2	6M	563.2	4.9%	–	²³
Prevention & Recovery (P&R)	FY2022	FY2025	12M	1,137	–	54%	²⁶
Reconstructive (Recon)	FY2022	FY2025	12M	1,111.1	–	65.8%	²⁶
P&R	2024-Q3	2024-Q3	9M	811	2.1%	–	¹⁷
Recon	2024-Q2	2024-Q3	3M	735.6	60.7%	–	¹⁷

Products & M&A (1/7 active+recent)#

Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.

Product/Line	Since	Status	Source
Innovation pipeline strengthening	2026-06	Launched	³¹
Arvis 2.0 Shoulder	2024-09	Launched	¹⁵
Altivate Reverse Glenoid system	2024-09	Launched	¹⁵
ROAM OA launch	2024-02	Launched	¹³
Lima Trabecular Titanium Cones for use with EMPOWR launch	2024-02	Launched	¹³
Arvis 2.0 launch	2024-02	Launched	¹³
Multi-year cadence of new product introductions across Recon and P&R	2024	Launched	¹¹

M&A (25)#

All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.

Acquisitions · 17Divestitures/exits · 8

Acquisitions

Transaction / stake	Date	Type	Source
Credit Facility Amendment No. 3	2025-12	Completed	²⁶
Strategic acquisitions (seven transactions)	2025-06	Completed	²²
Strategic purchases of economic interest on future royalty payments	2025-03	Completed	²¹
Five bolt-on acquisitions (three P&R, two Recon)	2025-03	Completed	²⁰
Seven transactions including three distributors, two businesses, and two intellectual property purchases	2025	Completed	²⁸
Seven acquisitions in 2025 (distributors, businesses, intellectual property)	2025	Completed	²⁶
Precision AI acquisition (3x)	2023-10	Completed	²⁶
Lima Acquisition (3x)	2023-09	Completed	²⁶
Acquisition of LimaCorporate S.p.A.	2023-09	Completed	¹³
SEAL asset acquisition (6x)	2023-07	Completed	²⁶
Novastep Acquisition - Minimally Invasive Surgery foot and ankle solutions	2023-06	Completed	²⁶
Novastep acquisition from Amplitude Surgical SA	2023-03	Completed	³
Novastep acquisition	2023	Completed	²⁶
Insight Medical Systems controlling interest acquisition	2022-09	Completed	⁵
Insight Medical Systems acquisition (ARVIS surgical navigation system)	2022-09	Completed	¹⁸
360 Med Care (KICo) Acquisition - Computer-assisted surgery distributor	2022-06	Completed	¹⁸
360 Med Care acquisition	2022-05	Completed	⁵

▸ More transactions (+2)

Divestitures / exits

Transaction / stake	Date	Type	Source
Sale of fabrication technology business	2025-12	Divested	²⁷
Dr Comfort Divestiture (3x)	2025-10	Divested	²⁶
Diabetic Footcare business unit divestiture from P&R segment	2025-10	Divested	²⁵
Hosiery business divestiture	2024-04	Divested	²²
Discontinued third-party OEM relationships (Recon segment)	2024	Divested	²⁰
Compression Hosiery Product Line Divestiture (3x)	2024	Divested	¹⁶
ESAB Separation (spin-off of fabrication technology business)	2022-04	Divested	³
ESAB Separation	2022	Divested	¹⁸

Reported KPIs (as disclosed) (138)#

Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.

Date	Period	KPI	Value / change	Source
2026-08-06	2026-Q2	Gross profit margin	61.6%	³¹
2026-08-06	2026-Q2	Adjusted gross profit margin	61.7%	³¹
2026-08-06	2026-Q2	Adjusted EBITDA margin (six months)	17.7%	³¹
2026-08-06	2026-Q2	Adjusted EBITDA margin	17.9%	³¹
2026-05-07	2026-Q1	Revolver available	906	²⁸
2026-05-07	2026-Q1	Recon Gross profit margin	69.1%	²⁸
2026-05-07	2026-Q1	Recon Adjusted EBITDA margin	22.9%	²⁸
2026-05-07	2026-Q1	P&R Gross profit margin	53.8%	²⁸
2026-05-07	2026-Q1	P&R Adjusted EBITDA margin	11.4%	²⁸
2026-05-07	2026-Q1	Operating income margin	1.1%	²⁸
2026-05-07	2026-Q1	Operating income	6.5 (USD in millions)	²⁸
2026-05-07	2026-Q1	Net loss	-8.5	²⁸
2026-05-07	2026-Q1	Gross profit margin	62.0%	²⁸
2026-05-07	2026-Q1	Gross profit	365.5 (USD in millions)	²⁸
2026-05-07	2026-Q1	Cash and cash equivalents	33.1 (USD in millions)	²⁸
2026-05-07	2026-Q1	Adjusted EBITDA margin	17.6%	²⁸
2026-02-26	FY2025	Weighted-average interest rate	5.23%	²⁶
2026-02-26	FY2025	Unrecognized tax benefits net liabilities	33.4 million	²⁶
2026-02-26	FY2025	Term Loan outstanding	688 million	²⁶
2026-02-26	FY2025	Term Loan Facility commitment	700 million	²⁶
2026-02-26	FY2025	Stock repurchase authorization remaining	100.0 million	²⁶
2026-02-26	FY2025	Revolver outstanding	157.2 million	²⁶
2026-02-26	FY2025	Revolver capacity	1.1 billion	²⁶
2026-02-26	FY2025	Other purchase obligations	135.1 million	²⁶
2026-02-26	FY2025	Operating cash flow	217.3 million	²⁶
2026-02-26	FY2025	Lease payment obligations	97.3 million	²⁶
2026-02-26	FY2025	International sales percentage	42%	²⁶
2026-02-26	FY2025	Contingent letters of credit and surety bonds	51.9 million	²⁶
2026-02-26	FY2025	Cash and cash equivalents	36.4 million	²⁶
2026-02-26	FY2025	Capital expenditures	197.4 million	²⁶
2026-02-26	FY2025	Allowance for credit losses	25.6 million	²⁶
2026-02-26	FY2025	2028 Notes outstanding	452 million	²⁶
2026-02-26	FY2025	2028 Notes interest rate	3.875%	²⁶
2026-02-26	2025-Q4	Adjusted EBITDA margin	19.4%	²⁷
2025-11-06	2025-Q3	Adjusted net income margin from continuing operations	7.9%	²⁵
2025-11-06	2025-Q3	Adjusted gross profit margin	60.3%	²⁵
2025-11-06	2025-Q3	Adjusted EBITDA margin (non-GAAP) - Three Months Ended September 27, 2024	17.9	²⁴
2025-11-06	2025-Q3	Adjusted EBITDA margin (non-GAAP) - Three Months Ended October 3, 2025	17.3	²⁴
2025-11-06	2025-Q3	Adjusted EBITDA margin (non-GAAP) - Nine Months Ended September 27, 2024	17.0	²⁴
2025-11-06	2025-Q3	Adjusted EBITDA margin (non-GAAP) - Nine Months Ended October 3, 2025	17.4	²⁴
2025-11-06	2025-Q3	Adjusted EBITDA margin	17.3%	²⁵
2025-08-07	2025-Q2	Overdraft facilities borrowing capacity	30.0	²²
2025-08-07	2025-Q2	Letters of credit and surety bonds outstanding	50.1	²²
2025-08-07	2025-Q2	Cash and cash equivalents	44.1 (USD in millions)	²²
2025-08-07	2025-Q2	Available on Revolver	325	²²
2025-05-08	2025-Q1	Gross profit margin (GAAP)	59.4%	²¹
2025-05-08	2025-Q1	Comparable Sales Growth rate	9.3	²⁰
2025-05-08	2025-Q1	Adjusted EBITDA margin (non-GAAP)	17.8	²⁰
2025-05-08	2025-Q1	Adjusted EBITDA margin	17.7%	²¹
2025-02-26	FY2024	Unrecognized income tax benefits	33.4 (USD millions)	¹⁸
2025-02-26	FY2024	Term Loan principal outstanding	377 (USD millions)	¹⁸
2025-02-26	FY2024	Revolver principal outstanding	503.1	¹⁸
2025-02-26	FY2024	Revolver available	397.0	¹⁸
2025-02-26	FY2024	Purchase obligations	130.6	¹⁸
2025-02-26	FY2024	Operating loss	(775.7)	¹⁸
2025-02-26	FY2024	Operating lease payment obligations	80.6	¹⁸
2025-02-26	FY2024	Net sales	2,107.6 (USD millions)	¹⁸
2025-02-26	FY2024	Net loss from continuing operations	(827.4)	¹⁸
2025-02-26	FY2024	Letters of credit and surety bonds outstanding	36.5	¹⁸
2025-02-26	FY2024	International sales percentage	41%	¹⁸
2025-02-26	FY2024	Gross profit margin	56.0%	¹⁸
2025-02-26	FY2024	Estimated future interest payments - Term Loan	51.3 (USD millions)	¹⁸
2025-02-26	FY2024	Estimated future interest payments - Revolver	136.0	¹⁸
2025-02-26	FY2024	Estimated future interest payments - 2028 Notes	59.5	¹⁸
2025-02-26	FY2024	Comparable Sales	2,102.8 (USD millions)	¹⁸
2025-02-26	FY2024	Cash and cash equivalents	48.2 (USD millions)	¹⁸
2025-02-26	FY2024	2028 Notes principal outstanding	449	¹⁸
2025-02-26	2024-Q4	Reconstructive Comparable Sales growth Q4 2024	10%	¹⁹
2025-02-26	2024-Q4	Reconstructive Comparable Sales growth FY 2024	9%	¹⁹
2025-02-26	2024-Q4	Prevention & Recovery Comparable Sales growth Q4 2024	3%	¹⁹
2025-02-26	2024-Q4	Prevention & Recovery Comparable Sales growth FY 2024	3%	¹⁹
2025-02-26	2024-Q4	Comparable Sales growth Q4 2024	6%	¹⁹
2025-02-26	2024-Q4	Comparable Sales growth FY 2024	6%	¹⁹
2025-02-26	2024-Q4	Adjusted EBITDA margin Q4 2024	20%	¹⁹
2025-02-26	2024-Q4	Adjusted EBITDA margin FY 2024	18%	¹⁹
2024-11-06	2024-Q3	Recon Comparable Sales growth (three months)	9%	¹⁷
2024-11-06	2024-Q3	P&R Comparable Sales growth (three months)	3%	¹⁷
2024-11-06	2024-Q3	Comparable Sales growth (three months)	6%	¹⁷
2024-11-06	2024-Q3	Comparable Sales Growth - Total (three months)	5.7	¹⁶
2024-11-06	2024-Q3	Comparable Sales Growth - Total (nine months)	5.3	¹⁶
2024-11-06	2024-Q3	Comparable Sales Growth - Recon (three months)	9.2	¹⁶
2024-11-06	2024-Q3	Comparable Sales Growth - Recon (nine months)	8.0	¹⁶
2024-11-06	2024-Q3	Comparable Sales Growth - P&R (three months)	2.9	¹⁶
2024-11-06	2024-Q3	Comparable Sales Growth - P&R (nine months)	3.0	¹⁶
2024-11-06	2024-Q3	Cash, cash equivalents and restricted cash	39.8 (USD millions)	¹⁶
2024-11-06	2024-Q3	Available on Revolver	385	¹⁶
2024-11-06	2024-Q3	Adjusted EBITDA margin (three months)	17.9%	¹⁷
2024-11-06	2024-Q3	Adjusted EBITDA margin (nine months)	17.0%	¹⁷
2024-08-07	2024-Q2	Recon comparable sales growth	7%	¹⁵
2024-08-07	2024-Q2	P&R comparable sales growth	3%	¹⁵
2024-08-07	2024-Q2	Comparable sales growth	5%	¹⁵
2024-08-07	2024-Q2	Available Revolver	385 million	¹⁴
2024-05-02	2024-Q1	Gross profit margin (GAAP)	57.7%	¹³
2024-05-02	2024-Q1	Cash, cash equivalents and restricted cash	74.5 (USD in millions)	¹²
2024-05-02	2024-Q1	Available on Revolver	400	¹²
2024-05-02	2024-Q1	Adjusted net income margin from continuing operations	5.4%	¹³
2024-05-02	2024-Q1	Adjusted gross profit margin (Non-GAAP)	58.7%	¹³
2024-05-02	2024-Q1	Adjusted EBITDA margin	16.1%	¹³
2024-02-22	FY2023	Weighted-average interest rate on Enovis Credit Agreement borrowings	6.58%	¹⁰
2024-02-22	FY2023	Senior secured leverage ratio covenant	3.75:1.00	¹⁰
2024-02-22	FY2023	Purchase obligations	145.9	¹⁰
2024-02-22	FY2023	Outstanding letters of credit	11.5	¹⁰
2024-02-22	FY2023	Net liabilities for unrecognized income tax benefits	34.1 (USD millions)	¹⁰
2024-02-22	FY2023	Fixed lease payment obligations	71.7	¹⁰
2024-02-22	FY2023	Cash and cash equivalents	44.8 (USD millions)	¹⁰
2024-02-22	FY2023	Available on Revolver	880.0	¹⁰
2024-02-22	FY2023	Allowance for credit losses	9.7	¹⁰
2024-02-22	FY2023	Adjusted EBITDA margin (non-GAAP) Total	15.8%	¹⁰
2024-02-22	FY2023	Adjusted EBITDA margin (non-GAAP) Recon	18.5%	¹⁰
2024-02-22	FY2023	Adjusted EBITDA margin (non-GAAP) P&R	14.2%	¹⁰
2024-02-22	FY2023	2028 Notes principal amount	460.0 (USD millions)	¹⁰
2024-02-22	FY2023	2028 Notes interest rate	3.875%	¹⁰
2024-02-22	2023-Q4	Adjusted gross margin (Non-GAAP)	58.6%	¹¹
2024-02-22	2023-Q4	Adjusted EBITDA margin	18%	¹¹
2023-11-07	2023-Q3	US hip/knee growth	+18%	⁹
2023-11-07	2023-Q3	Reconstructive segment growth	16%	⁹
2023-11-07	2023-Q3	Reconstructive organic growth	10%	⁹
2023-11-07	2023-Q3	Prevention and Recovery segment growth	5%	⁹
2023-11-07	2023-Q3	Prevention and Recovery organic growth	4%	⁹
2023-11-07	2023-Q3	Adjusted EBITDA margin	15.7%	⁹
2023-08-03	2023-Q2	Gross profit margin Q2 2023	58.0	⁵
2023-08-03	2023-Q2	Gross profit margin Q2 2022	54.6	⁵
2023-08-03	2023-Q2	Gross profit margin H1 2023	57.9	⁵
2023-08-03	2023-Q2	Gross profit margin H1 2022	54.9	⁵
2023-08-03	2023-Q2	Adjusted EBITDA margin Q2 2023	15.3	⁵
2023-08-03	2023-Q2	Adjusted EBITDA margin Q2 2022	14.2	⁵
2023-08-03	2023-Q2	Adjusted EBITDA margin H1 2023	14.6	⁵
2023-08-03	2023-Q2	Adjusted EBITDA margin H1 2022	13.5	⁵
2023-08-03	2023-Q2	Gross margin	58.0%	⁶
2023-08-03	2023-Q2	Adjusted EBITDA margin	15.3%	⁶
2023-05-04	2023-Q1	Operating loss margin (GAAP) prior year	-8.2	³
2023-05-04	2023-Q1	Operating loss margin (GAAP)	-6.1	³
2023-05-04	2023-Q1	Gross profit margin prior year	54.8	³
2023-05-04	2023-Q1	Gross profit margin	57.9	³
2023-05-04	2023-Q1	Adjusted net income margin from continuing operations	5.9%	⁴
2023-05-04	2023-Q1	Adjusted EBITDA margin (Non-GAAP) prior year	12.7	³
2023-05-04	2023-Q1	Adjusted EBITDA margin (non-GAAP)	13.9	³
2023-05-04	2023-Q1	Adjusted EBITDA margin	13.9%	⁴

▸ Earlier KPIs (+123)

Guidance Tracking (latest per metric/period · 8/14)#

All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.

Actuals: revenue in $m · EPS in $ per share

For period	Guided on	Metric	Guided	Actual	Verdict	Direction	Source
FY2026	2026-08-06	Organic revenue growth	4–6%	–	pending	confirmed	³¹
FY2026	2026-05-07	Free cash flow conversion	25%	–	pending	confirmed	³¹
FY2026	2026-02-26	Revenue	2,310–2,370	–	pending	confirmed	³¹
FY2026	2026-02-26	EPS (non-GAAP)	3.52–3.73	–	pending	confirmed	³¹
FY2026	2026-02-26	EBITDA (adjusted)	425–435	–	pending	confirmed	³¹
FY2025	2025-08-07	EBITDA (adjusted)	395–405	–	–	raised	²⁵
FY2025	2025-05-08	Revenue	2,240–2,270	2,248	in line	confirmed	²⁵
FY2025	2025-02-26	EPS (non-GAAP)	3.1–3.25	3.3	beat	raised	²⁵
FY2024	2024-11-06	EPS (non-GAAP)	2.75–2.8	2.84	beat	raised	¹⁷
FY2024	2024-08-07	Revenue	2,100	2,107.6	beat	confirmed	¹⁷
FY2024	2024-05-02	EBITDA (adjusted)	373–378	216.9	miss	confirmed	¹⁷
FY2023	2023-11-07	EPS (non-GAAP)	2.3–2.4	2.4	in line	raised	⁹
FY2023	2023-11-07	Revenue growth (YoY)	7.4–7.6%	–	–	raised	⁹
FY2023	2023-05-04	EBITDA (adjusted)	264–270	269.2	in line	raised	⁹

Development#

A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.

FY2026

Enovis Corporation reported net sales of $589.2 million in Q1 2026 (+5.4% year-over-year) and $582.8 million in Q2 2026 (+3.2%), with half-year net sales increasing 4.3%, driven by organic growth and favorable foreign currency translation, partly offset by the October 2025 divestiture of Dr. Comfort Footcare Solutions U.S. operations (²⁸, ³⁰). The Reconstructive segment led performance with reported growth of 10.8% in Q1 and 7.5% in Q2, while the Prevention & Recovery segment was essentially flat on an organic basis across both quarters (²⁸, ²⁹, ³⁰). Gross margin expanded 260 basis points to 62.0% in Q1, and adjusted EBITDA margins improved to 17.6% in Q1 and 17.9% in Q2; adjusted EPS rose from $0.72 to $0.90 year-over-year in Q2 (²⁸, ³¹). Net income remained negative at -$8.4 million in Q1 and -$1.0 million in Q2, while six-month operating cash flow improved $52.8 million year-over-year to $99.0 million (³⁰). Full-year 2026 guidance was reaffirmed at $2.31-2.37 billion in revenue, $425-435 million in adjusted EBITDA, $3.52-3.73 in adjusted EPS, and free cash flow conversion of 25% or higher (³¹).

FY2025

Enovis Corp reported full-year 2025 net sales of $2,248.0 million, an increase of 6.7% from $2,107.6 million in 2024, with Reconstructive segment net sales rising 10% to $1,111.1 million and Prevention & Recovery segment net sales rising 3.6% to $1,137.0 million (²⁶). Gross profit margin improved 380 basis points to 59.8%, and adjusted EBITDA increased to $403.0 million from $376.5 million in the prior year, while full-year free cash flow was $19.9 million (²⁶, ²⁷). The reported net loss of $1,184.4 million for FY2025 reflects non-cash goodwill impairment charges totaling $1,049.8 million recorded in two tranches - $540.8 million in Q3 and $501.0 million in Q4 - both attributed to a sustained decline in the company's publicly quoted share price and market capitalization (²⁶, ²⁷). Material corporate actions during the year included seven bolt-on acquisitions for $36.9 million total consideration, the divestiture of Dr. Comfort Footcare Solutions for up to $60 million completed in October 2025, appointment of a new CEO effective May 2025, and an amendment to the credit agreement in December 2025 extending revolver and term loan maturity to 2030 (²⁶).

FY2024

Enovis Corporation reported FY2024 net sales of $2,107.6 million, an increase of 23.5% versus 2023, driven primarily by $338.1 million in contributions from the Lima and Novastep acquisitions within the Reconstructive segment ¹⁸. Comparable sales grew 5.6% for the full year, reflecting 8.2% volume and market share gains in Recon and 3.0% organic growth in Prevention & Recovery ¹⁸. Adjusted EBITDA rose to $376.5 million (17.9% of net sales) from $269.2 million (15.8%) in 2023, while gross profit margin contracted 200 basis points to 56.0%, primarily due to $51.6 million of inventory fair value step-up amortization charges related to the Lima Acquisition ¹⁸. The company recorded a non-cash goodwill impairment charge of $645 million in 2024, tied to a sustained decline in its publicly quoted share price and market capitalization relative to the carrying values of its Reconstructive and Prevention & Recovery reporting units, resulting in a net loss from continuing operations of $827.4 million compared to $53.8 million in 2023 ¹⁸ ¹⁹. Operating cash flow was $113.5 million versus $135.0 million in 2023, with free cash flow of negative $67.2 million, impacted by $180.7 million in capital expenditures and $73.7 million of working capital used primarily from international business growth ¹⁸.

FY2023

Enovis Corporation reported FY 2023 net sales of $1,707.2 million, an increase of 9.2% year-over-year driven by 8% organic growth across both the Prevention & Recovery and Reconstructive segments ¹¹⁹. Gross profit margin expanded to 58.0% from 55.6% in 2022, and adjusted EBITDA grew to $269.2 million from $236.1 million in the prior year, representing a margin improvement of approximately 70 basis points to approximately 16% of net sales ¹⁰ ¹¹. The company recorded a full-year operating loss of $65.7 million and a net loss of $33.3 million ($0.61 loss per diluted share), while adjusted diluted EPS reached $2.40 ¹¹⁹. Enovis completed three acquisitions within the Reconstructive segment during the year – Novastep for $96.9 million in June, SEAL for $28.2 million in July, and Precision AI in October 2023 – and issued $460 million in senior unsecured convertible notes at 3.875% in October 2023 ¹⁰. A definitive agreement to acquire LimaCorporate S.p.A. for approximately €800 million enterprise value was announced in Q3 2023, with the transaction closing on January 3, 2024 ⁹ ¹⁰.

Sources: official investor relations documents#

All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.

49 documents · 2016 – 2026 · SEC EDGAR (USA)

#	Document type	Published	Link
#1 / #101	8-K-EX99.1	2023-02-23	Open
#2	10-K	2023-03-01	Open
#3	10-Q	2023-05-04	Open
#4 / #104	8-K-EX99.1	2023-05-04	Open
#5	10-Q	2023-08-03	Open
#6 / #106	8-K-EX99.1	2023-08-03	Open
#7	8-K-EX99.1	2023-10-19	Open
#8	10-Q	2023-11-07	Open
#9 / #109	8-K-EX99.1	2023-11-07	Open
#10	10-K	2024-02-22	Open
#11 / #111	8-K-EX99.1	2024-02-22	Open
#12	10-Q	2024-05-02	Open
#13 / #113	8-K-EX99.1	2024-05-02	Open
#14	10-Q	2024-08-07	Open
#15 / #115	8-K-EX99.1	2024-08-07	Open
#16	10-Q	2024-11-06	Open
#17 / #117	8-K-EX99.1	2024-11-06	Open
#18	10-K	2025-02-26	Open
#19 / #119	8-K-EX99.1	2025-02-26	Open
#20	10-Q	2025-05-08	Open
#21 / #121	8-K-EX99.1	2025-05-08	Open
#22	10-Q	2025-08-07	Open
#23 / #123	8-K-EX99.1	2025-08-07	Open
#24	10-Q	2025-11-06	Open
#25 / #125	8-K-EX99.1	2025-11-06	Open
#26	10-K	2026-02-26	Open
#27 / #127	8-K-EX99.1	2026-02-26	Open
#28	10-Q	2026-05-07	Open
#29 / #129	8-K-EX99.1	2026-05-07	Open
#30	10-Q	2026-08-06	Open
#31 / #131	8-K-EX99.1	2026-08-06	Open

▸ More rows (+16)

Older sources (+18)

#	Document type	Published	Link
#201	10-Q	2016-05-03	Open
#202	10-Q	2016-07-28	Open
#203	10-Q	2016-10-27	Open
#204	10-K	2017-02-14	Open
#208	10-K	2017-02-14	Open
#205	10-Q	2017-05-05	Open
#206	10-Q	2017-07-28	Open
#207	10-Q	2017-11-06	Open
#212	10-K	2018-02-16	Open
#210	10-Q	2018-08-06	Open
#211	10-Q	2018-10-25	Open
#213	10-K	2019-02-21	Open
#209	10-Q	2019-05-08	Open
#217	10-K	2020-02-24	Open
#214	10-Q	2020-05-07	Open
#215	10-Q	2020-08-06	Open
#216	10-Q	2020-10-29	Open
#218	10-Q	2021-07-28	Open

▸ More rows (+3)

FAQ#

Is there a management forecast (guidance) for FY2026?

Yes. Management has issued targets for FY2026, including Organic revenue growth. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Where can I find the official investor relations documents of Enovis Corporation?

The sources chapter links all 64 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.

More reports#

Same sector and country

Bloomin' Brands Inc. (BLMN)US0942351083Period 2026-Q2Updated 2026-09-06Margin expanding · Guidance raised The Cigna Group (CI)US1255231003Period 2026-Q2Updated 2026-09-06Guidance raised · Strategic pivot Columbus McKinnon Corporation (CMCO)US1993331057Period 2027-Q1Updated 2026-09-06Revenue accelerating · Order intake

Enovis Corporation ENOV

Business Model#

Current Status#

Price & Chart#

Share-Price Drivers#

Event Timeline#

2026-Q2 · Apr – Jun 2026

2026-Q1 · Jan – Mar 2026

2025-Q4 · Oct – Dec 2025

2025-Q3 · Jul – Sep 2025

2025-Q2 · Apr – Jun 2025

2025-Q1 · Jan – Mar 2025

FY2024 · Jan – Dec 2024

2024-Q4 · Oct – Dec 2024

2024-Q3 · Jul – Sep 2024

2024-Q2 · Apr – Jun 2024

2024-Q1 · Jan – Mar 2024

2023-Q4 · Oct – Dec 2023

2023-Q3 · Jul – Sep 2023

2023-Q2 · Apr – Jun 2023

2023-Q1 · Jan – Mar 2023

Key Figures ($m)#

Fiscal years

Quarters

Balance Sheet & Cash Flow ($m)#

Fiscal years

Quarters

Revenue by Type (as of 2026-Q2 · USDm · 10/12)#

Products & M&A (1/7 active+recent)#

M&A (25)#

Acquisitions

Divestitures / exits

Reported KPIs (as disclosed) (138)#

Guidance Tracking (latest per metric/period · 8/14)#

Development#

Sources: official investor relations documents#

FAQ#

More reports#

Recently updated

Same sector and country